公司资料
Harmony Biosciences 股价、新闻与催化剂
- 股票代码:
- HRMY
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
38.14 USD (+0.05%)
收盘价
最后更新: 2026年8月17日
1.79B USD
市值
股价为何变动
As of Aug 17, 2026, HRMY was little changed and closed at $38.14. No new same-company headline was identified in the current news window.
公司概览
Sleep and Neurologic Disorders
Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling.
WAKIX Franchise
WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the company's principal commercial product.
Pitolisant Lifecycle Programs
Harmony is extending pitolisant through a gastro-resistant formulation, a higher-dose program and a newly acquired amorphous form intended to support additional central-nervous-system indications.
Orexin-2 Program
BP-205 is an orexin-2 receptor agonist in Phase 1 development and is intended to complement Harmony's existing wake-promoting franchise with a distinct mechanism.
未来催化剂
- NDA submission for a gastro-resistant formulation of pitolisant in the second quarter of 2026.
- Phase 1 pharmacokinetic data for BP-205 around mid-2026.
- Phase 3 data for high-dose pitolisant in 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。